Результаты поиска

Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer.

UnlabelledThis study aimed to assess the efficacy and safety of combination treatment with lenalidomide and cetuximab in KRAS-mutant metastatic colorectal cancer patients. This was a phase II multicenter, open-label trial comprising a safety lead-in phase (phase IIa) to determine the maximum tolerated dose, and a randomized proof of concept phase (phase IIb) to determine the response rate of lenalidomide plus cetuximab combination therapy. Phase IIa treatment comprised oral lenalidomide (starting dose 25 mg/day) and intravenous cetuximab (400 mg/m(2) followed by weekly 250 mg/m(2)) in 28-day c

Совпадение в полном тексте источника
… 4.8%) | 0 General physical health deterioration | 1 (12.5%) | 1 (12.5%) | 0 | 0 | 0 Arthralgia | 1 (12.5%) | 1 (12.5%) | 0 | 0 | 0 Photosensitivity reaction | 1 (12.5%) | 1 (12.5%) | 0 | 0 | 0 Hypersensitivity | 0 | 1 (12.5%) | 0 | 0 | 1 (4.8%) Skin hyperpigmentation | 0 | 1 (12.5%) | 0 | 0 | 1 (4.8%) Hypertrichosis …

Azathioprine for people with multiple sclerosis.

BackgroundMultiple sclerosis (MS) is an immune-mediated, chronic, inflammatory demyelinating disease of the central nervous system, impacting around 2.8 million people worldwide. Characterised by recurrent relapses or progression, or both, it represents a substantial global health burden, affecting people, predominantly women, at a young age (the mean age of diagnosis is 32 years). Azathioprine is used to treat chronic inflammatory and autoimmune diseases, and it is used in clinical practice as an off-label intervention for MS, especially where access to on-label disease-modifying treatments (

Comprehensive Diagnosis and Management of POEMS Syndrome.

Polyneuropathy Organomegaly, Endocrinopathy, Monoclonal protein and Skin changes syndrome is a rare multisystem condition with a range of manifestations which are often overlooked as trivial comorbidities, until their whole triggers the possibility of the diagnosis. The diagnosis is typically delayed by 12-16 months, by which time patients can be severely disabled. There are no established consensus guidelines. We provide clinicians a comprehensive blueprint for managing POEMS from diagnostic suspicion through the work-up, selection of therapy, follow-up, and treatment of relapse based on publ

Совпадение в полном тексте источника
… Minor criteria—one required | Organomegaly • Splenomegaly, hepatomegaly, lymphadenopathy Extravascular volume overload • Peripheral edema, ascites, pleural effusions Endocrinopathy • Adrenal, pituitary, gonadal, parathyroid • Thyroid and pancreatic (nondiagnostic) Skin changes • Hyperpigmentation, hypertrichosis …

Sclerosing diseases of the skin.

Sclerosing skin diseases comprise a group of distinct dermatological conditions characterized by fibrotic changes that may severely impair patients' quality of life. These conditions often present with cutaneous manifestations and, in some cases, may extend to extracutaneous tissues, potentially resulting in significant morbidity and mortality. This review explores the current understanding of the four most prevalent sclerosing skin diseases - localized scleroderma (morphea), systemic sclerosis (SSc), scleromyxedema, and scleredema adultorum of Buschke - as well as sclerotic conditions induced

Совпадение в полном тексте источника
… Affected individuals often display mild hypertrichosis. SSS is caused by mutations in the FBN1 gene, which encodes fibrillin‐1. The resulting dysregulation leads to increased TGF‐β activity, which contributes to the characteristic skin induration. 103 CONFLICT OF INTEREST STATEMENT None. …

Recent Advances in the Treatment and Supportive Care of POEMS Syndrome.

POEMS is a rare clonal plasma cell disorder characterized by multi-systemic features that include demyelinating peripheral neuropathy, organomegaly, endocrinopathy, presence of monoclonal proteins (M-protein), and skin changes. Even though the pathophysiology is poorly understood, recent studies suggest that both clonal and polyclonal plasmacytosis leading to the production of pro-inflammatory cytokines and angiogenic mediators play the central role. These mediators including vascular endothelial growth factor (VEGF) are the driving forces of the syndrome. The diagnosis of POEMS is not always

Совпадение в полном тексте источника
… Polyneuropathy, skin hyperpigmentation, edema, and hypertrichosis in localized osteosclerotic myeloma Neurology 1977 27 675 10.1212/WNL.27.7.675 559975 50. Suh Y.-G. Suh C.-O. Kim J.S. Kim S.-J. Pyun H.O. Cho J. Radiotherapy for solitary plasmacytoma of bone and soft tissue Ann. …

Targeted Drug Delivery in Periorbital Non-Melanocytic Skin Malignancies.

Targeted drug delivery has emerged as a transformative approach in the treatment of periorbital skin malignancies, offering the potential for enhanced efficacy and reduced side effects compared to traditional therapies. This review provides a comprehensive overview of targeted therapies in the context of periorbital malignancies, including basal cell carcinoma, squamous cell carcinoma, sebaceous gland carcinoma, and Merkel cell carcinoma. It explores the mechanisms of action for various targeted therapies, such as monoclonal antibodies, small molecule inhibitors, and immunotherapies, and their

Совпадение в полном тексте источника
… Hypertrichosis and periocular edema are common and can be particularly distressing for patients due to their impact on appearance. …

Monoclonal Antibodies Approved for Cancer Therapy

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… agencies are for the possibility of interstitial lung disease which was recorded in 4 of 1570 patients (0.25 %); a variety of dermatologic events already known to occur, for example, “acneiform” rash (with an incidence of 76–88 %, up to 17 % serious), xerosis and fissuring, paronychial inflammation, hypertrichosis …

A novel method for handling pre-existing conditions in multivariate prediction model development for COVID-19 death in the Department of Veterans Affairs.

Many mathematical models have been proposed to predict death following the Coronavirus Disease 2019 (COVID-19); all started with comorbidity subsets for this still-little understood disease. Thus, we derived a novel predicted probability of death model (PDeathDx) upon all diagnostic codes documented in the Department of Veterans Affairs. We present the conceptual underpinnings and analytic approach in estimating the independent contribution of pre-existing conditions. This is the largest study to-date following patients with COVID-19 to predict mortality. Cases were identified with at least on

Совпадение в полном тексте источника
… infertility | 2364 (0.6958) | 0.0161 | 0.0536 | 0.2999 | 0.1524–0.5904 N84 | N84.1 | Polyp of female genital tract | 1403 (0.4129) | 0.0157 | 0.0535 | 0.2932 | 0.1204–0.7138 N73 | N73.9 | Other female pelvic inflammatory disease | 1373 (0.4041) | 0.0138 | 0.0535 | 0.2587 | 0.0992–0.6745 L68 | L68.0 | Hypertrichosis …

Monoclonal Gammopathies of Clinical Significance: A Critical Appraisal.

Monoclonal gammopathies of clinical significance (MGCSs) represent a group of diseases featuring the association of a nonmalignant B cells or plasma cells clone, the production of an M-protein, and singularly, the existence of organ damage. They present a current framework that is difficult to approach from a practical clinical perspective. Several points should be addressed in order to move further toward a better understanding. Overall, these entities are only partially included in the international classifications of diseases. Its definition and classification remain ambiguous. Remarkably,

Совпадение в полном тексте источника
… The skin lesions associated with POEMS syndrome occur in more than two-thirds of patients, including most commonly hyperpigmentation and hypertrichosis, although acrocyanosis, plethora, telangiectasia, and skin thickening have also been reported. …

Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals.

Myasthenia gravis (MG) is a chronic, fluctuating, antibody-mediated autoimmune disorder directed against the post-synaptic neuromuscular junctions of skeletal muscles, resulting in a wide spectrum of manifestations ranging from mild to potentially fatal. Given its unique natural course, designing an ideal trial design for MG has been wrought with difficulties and evidence in favour of several of the conventional agents is weak as per current standards. Despite this, acetylcholinesterases and corticosteroids have remained the cornerstones of treatment for several decades with intravenous immuno

Совпадение в полном тексте источника
… While comparative studies are not available in MG, in other disorders tacrolimus has significantly less cosmetic side effects such as gum hypertrophy and hypertrichosis compared with CsA [ 90 ]. …

Hematology

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Hematology

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Abstracts from the ISSAID 2021 Periodic Congress : Virtual. May - Dec 2021

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Abstracts from the 53rd European Society of Human Genetics (ESHG) Conference: e-Posters.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

2020 ACVIM Forum On Demand Research Abstract Program.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Резюме докладов 53rd Конференция Европейского общества генетики человека: интерактивные электронные постеры.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Резюме докладов 51st Конференция Европейского общества генетики человека: плакаты

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Ход работы сессии 31st Европейский педиатрический конгресс по педиатрии: часть 1.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Abstracts

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Selected Abstracts from the 12th Annual Meeting of the Clinical Immunology Society: 2021 Virtual Annual Meeting: Immune Deficiency and Dysregulation North American Conference.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.